Compounds > licochalcone d
Page last updated: 2024-11-12

licochalcone d

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

licochalcone D: isolated from Glycyrrhiza inflata; inhibits phosphorylation of NF-kappaB p65 in LPS signaling pathway [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

FloraRankFlora DefinitionFamilyFamily Definition
GlycyrrhizagenusA genus of leguminous herbs or shrubs whose roots yield GLYCYRRHETINIC ACID and its derivative, CARBENOXOLONE.[MeSH]FabaceaeThe large family of plants characterized by pods. Some are edible and some cause LATHYRISM or FAVISM and other forms of poisoning. Other species yield useful materials like gums from ACACIA and various LECTINS like PHYTOHEMAGGLUTININS from PHASEOLUS. Many of them harbor NITROGEN FIXATION bacteria on their roots. Many but not all species of beans belong to this family.[MeSH]

Cross-References

ID SourceID
PubMed CID10473311
CHEMBL ID1644932
MeSH IDM0536803

Synonyms (23)

Synonym
LMPK12120425
licochalcone d
CHEMBL1644932
licochalcone d [mi]
(2e)-3-(3,4-dihydroxy-2-methoxyphenyl)-1-(4-hydroxy-3-(3-methyl-2-butenyl)phenyl)-2-propen-1-one
2-propen-1-one, 3-(3,4-dihydroxy-2-methoxyphenyl)-1-(4-hydroxy-3-(3-methyl-2-butenyl)phenyl)-, (e)-
144506-15-0
unii-3p0sh94v09
3p0sh94v09 ,
2-propen-1-one, 3-(3,4-dihydroxy-2-methoxyphenyl)-1-(4-hydroxy-3-(3-methyl-2-butenyl)phenyl)-, (2e)-
S6899
DTXSID00162738
bdbm50483309
AKOS037515337
HY-N4187
CS-0032380
Q27257833
(e)-3-(3,4-dihydroxy-2-methoxyphenyl)-1-[4-hydroxy-3-(3-methylbut-2-enyl)phenyl]prop-2-en-1-one
(e)-3-(3,4-dihydroxy-2-methoxyphenyl)-1-(4-hydroxy-3-(3-methylbut-2-en-1-yl)phenyl)prop-2-en-1-one
MS-25526
2-propen-1-one, 3-(3,4-dihydroxy-2-methoxyphenyl)-1-[4-hydroxy-3-(3-methyl-2-butenyl)p henyl]-, (e)-
XL173147
E88806
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID1061196Cytotoxicity against mouse RAW264.7 cells assessed as cell viability at 2 uM after 24 hrs by MTS assay2014Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1
Synthesis of licochalcone analogues with increased anti-inflammatory activity.
AID1061200Antiinflammatory activity in RBL2H3 cells assessed as inhibition of degranulation2014Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1
Synthesis of licochalcone analogues with increased anti-inflammatory activity.
AID549515Inhibition of Influenza A H1N1 virus neuraminidase activity after 2 hrs by spectrofluorometry2011Bioorganic & medicinal chemistry letters, Jan-01, Volume: 21, Issue:1
Chalcones as novel influenza A (H1N1) neuraminidase inhibitors from Glycyrrhiza inflata.
AID549518Inhibition of Influenza A H9N2 virus neuraminidase activity after 2 hrs by spectrofluorometry2011Bioorganic & medicinal chemistry letters, Jan-01, Volume: 21, Issue:1
Chalcones as novel influenza A (H1N1) neuraminidase inhibitors from Glycyrrhiza inflata.
AID1463921Activation of Nrf2 (unknown origin) expressed in human HepG2 cells at 2.5 to 20 uM incubated for 6 hrs by ARE-driven luciferase reporter gene assay2017Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20
Nrf2 activators from Glycyrrhiza inflata and their hepatoprotective activities against CCl
AID549519Noncompetitive inhibition of Influenza A H1N1 virus neuraminidase activity by Lineweaver-Burk plot analysis2011Bioorganic & medicinal chemistry letters, Jan-01, Volume: 21, Issue:1
Chalcones as novel influenza A (H1N1) neuraminidase inhibitors from Glycyrrhiza inflata.
AID1061199Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-stimulated nitric oxide production at 2 uM after 18 hrs by Griess assay relative to control2014Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1
Synthesis of licochalcone analogues with increased anti-inflammatory activity.
AID1463920Activation of Nrf2 (unknown origin) expressed in human HepG2 cells at 10 uM incubated for 6 hrs by ARE-driven luciferase reporter gene assay relative to untreated control2017Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20
Nrf2 activators from Glycyrrhiza inflata and their hepatoprotective activities against CCl
AID1061198Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-stimulated nitric oxide production at 20 uM after 18 hrs by Griess assay relative to control2014Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1
Synthesis of licochalcone analogues with increased anti-inflammatory activity.
AID1463923Cytotoxicity in human HepG2 cells expressing Nrf2/ARE-driven luciferase at 20 to 40 uM incubated for 6 hrs2017Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20
Nrf2 activators from Glycyrrhiza inflata and their hepatoprotective activities against CCl
AID549521Inhibition of Clostridium perfringens neuraminidase2011Bioorganic & medicinal chemistry letters, Jan-01, Volume: 21, Issue:1
Chalcones as novel influenza A (H1N1) neuraminidase inhibitors from Glycyrrhiza inflata.
AID1061197Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-stimulated nitric oxide production after 18 hrs by Griess assay2014Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1
Synthesis of licochalcone analogues with increased anti-inflammatory activity.
AID1061195Cytotoxicity against mouse RAW264.7 cells assessed as cell viability at 20 uM after 24 hrs by MTS assay2014Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1
Synthesis of licochalcone analogues with increased anti-inflammatory activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (9.09)29.6817
2010's7 (63.64)24.3611
2020's3 (27.27)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 19.27

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index19.27 (24.57)
Research Supply Index2.48 (2.92)
Research Growth Index5.56 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index3.00 (0.95)

This Compound (19.27)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
1-anilino-8-naphthalenesulfonate
1-anilino-8-naphthalenesulfonate: RN given refers to parent cpd. 8-anilinonaphthalene-1-sulfonic acid : A naphthalenesulfonic acid that is naphthalene-1-sulfonic acid substituted by a phenylamino group at position 8.		2.3110aminonaphthalene;
naphthalenesulfonic acid		fluorescent probe
galactose
galactopyranose : The pyranose form of galactose.		2.3110D-galactose;
galactopyranose		Escherichia coli metabolite;
mouse metabolite
malondialdehyde
Malondialdehyde: The dialdehyde of malonic acid.. malonaldehyde : A dialdehyde that is propane substituted by two oxo groups at the terminal carbon atoms respectively. A biomarker of oxidative damage to lipids caused by smoking, it exists in vivo mainly in the enol form.		2.1110dialdehydebiomarker
oseltamivir
Oseltamivir: An acetamido cyclohexene that is a structural homolog of SIALIC ACID and inhibits NEURAMINIDASE.. oseltamivir : A cyclohexenecarboxylate ester that is the ethyl ester of oseltamivir acid. An antiviral prodrug (it is hydrolysed to the active free carboxylic acid in the liver), it is used to slow the spread of influenza.		2.0610acetamides;
amino acid ester;
cyclohexenecarboxylate ester;
primary amino compound		antiviral drug;
EC 3.2.1.18 (exo-alpha-sialidase) inhibitor;
environmental contaminant;
prodrug;
xenobiotic
indicine
indicine: RN given refers to (1R-(1alpha,7(2R*,3S*),7abeta))-isomer		2.0510carboxylic ester;
pyrrolizines
liquiritigenin
liquiritigenin: structure given in first source; isolated from Pterocarpus marsupium. 4',7-dihydroxyflavanone : A dihydroxyflavanone in which the two hydroxy substituents are located at positions 4' and 7.. liquiritigenin : A dihydroxyflavanone compound having the two hydroxy substituents at the 4'- and 7-positions. Isolated from the root of Glycyrrhizae uralensis, it is a selective agonist for oestrogen receptor beta.		2.15104',7-dihydroxyflavanonehormone agonist;
plant metabolite
gefitinib
[no description available]		7.2510aromatic ether;
monochlorobenzenes;
monofluorobenzenes;
morpholines;
quinazolines;
secondary amino compound;
tertiary amino compound		antineoplastic agent;
epidermal growth factor receptor antagonist
glabridin
[no description available]		2.1510hydroxyisoflavansantiplasmodial drug
6,8-diprenylgenistein
6,8-diprenylgenistein: a lysoPAF acetyltransferase inhibitor isolated from licorice root; structure in first source. 5,7,4'-trihydroxy-6,8-diprenylisoflavone : A member of the class of 7-hydroxyisoflavones that is genistein substituted by prenyl groups at positions 6 and 8. It has been isolated from Derris scandens and Glycyrrhiza uralensis.		2.15107-hydroxyisoflavonesantibacterial agent;
plant metabolite
Euchrestaflavanone A
[no description available]		2.1510flavanones
isoliquiritigenin
[no description available]		2.7930chalconesantineoplastic agent;
biological pigment;
EC 1.14.18.1 (tyrosinase) inhibitor;
GABA modulator;
geroprotector;
metabolite;
NMDA receptor antagonist
formononetin
[no description available]		2.15104'-methoxyisoflavones;
7-hydroxyisoflavones		phytoestrogen;
plant metabolite
2'-hydroxyformononetin
2'-hydroxyformononetin : A member of the class of 4'-methoxyisoflavones that is formononetin with a hydroxy group at the 2'position.		2.15104'-methoxyisoflavones;
7-hydroxyisoflavones		anti-inflammatory agent
genistein
[no description available]		2.15107-hydroxyisoflavonesantineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
geroprotector;
human urinary metabolite;
phytoestrogen;
plant metabolite;
tyrosine kinase inhibitor
isobavachalcone
isobavachalcone: RN given for (E)-isomer; structure in first source. isobavachalcone : A member of the class of chalcones that is trans-chalcone substituted by hydroxy groups at positions 4, 2' and 4' and a prenyl group at position 3'.		2.1510chalcones;
polyphenol		antibacterial agent;
metabolite;
platelet aggregation inhibitor
licoisoflavone a
licoisoflavone A: from Sophra mooracroftiana; structure in first source. licoisoflavone A : A member of the class of 7-hydroxyisoflavones that is 7-hydroxyisoflavone substituted by additional hydroxy groups at positions 5, 2' and 4' and a prenyl group at position 3'.		2.15107-hydroxyisoflavonesmetabolite
wighteone
wighteone : A member of the class of 7-hydroxyisoflavones that is isoflavone substituted by hydroxy groups at positions 5, 7 and 4' and a prenyl group at position 6. It has been isolated from Ficus mucuso.		2.15107-hydroxyisoflavonesantifungal agent;
plant metabolite
4',7-dihydroxyflavone
4',7-dihydroxyflavone: inducer of nod gene. 4',7-dihydroxyflavone : A dihydroxyflavone in which the two hydroxy substituents are located at positions 4' and 7.		2.1510dihydroxyflavonemetabolite
eurycarpin b
eurycarpin B: from the roots of Glycyrrhiza eurycarpa; structure in first source		2.1510isoflavonoid
licochalcone a
licochalcone A: has both anti-inflammatory and antineoplastic activities; structure given in first source; isolated from root of Glycyrrhiza inflata; RN given refers to (E)-isomer		8.250chalcones
licochalcone b
licochalcone B: isolated from Glycyrrhiza inflata; inhibits phosphorylation of NF-kappaB p65 in LPS signaling pathway; structure in first source		8.0240chalcones
Licoflavone A
[no description available]		2.1510flavones
7,4'-dihydroxy-3'-methoxyisoflavone
7,4'-dihydroxy-3'-methoxyisoflavone : A member of the class of 7-hydroxyisoflavones that is 7,4'-dihydroxyisoflavone substituted by a methoxy group at position 3'. It is isolated from the heart woods of Maackia amurensis subsp buergeri and Dalbergia louveli and exhibits antiplasmodial ativity.		2.15107-hydroxyisoflavones;
methoxyisoflavone		antiplasmodial drug;
metabolite
licoisoflavone b
licoisoflavone B: from Sophra mooracroftiana; structure in first source		2.1510
semilicoisoflavone b
semilicoisoflavone B: isolated from Glycyrrhiza uralensis; structure in first source. semilicoisoflavone B : A member of the class of 7-hydroxyisoflavones that is 2',2'-dimethyl-2'H,4H-3,6'-bichromen-4-one substituted by hydroxy groups at positions 5, 7 and 8'. It has been isolated from Glycyrrhiza uralensis.		2.15107-hydroxyisoflavonesEC 1.1.1.21 (aldehyde reductase) inhibitor;
plant metabolite
alpinumisoflavone
alpinumisoflavone: extract from twigs of poisonous British plant		2.1510isoflavanonesmetabolite
licochalcone c
licochalcone C: has cardioprotective, antioxidant, anti-inflammatory and anti-apoptotic activities; isolated from licorice; structure in first source		2.8330
licoflavone c
licoflavone C: Antimutagenic Agent; a naturally occurring prenyl-flavone extracted from Genista ephedroides; structure in first source		2.1510
Kanzonol B
[no description available]		2.1510chalcones
2',3,4,4'-tetrahydroxy-5-prenylchalcone
[no description available]		2.0610
Licoflavone B
licoflavone B: Schistosomicide from Glycyrrhiza inflata; structure in first source		2.1510flavones
11-deoxy glycyrrhetinic acid
[no description available]		2.1510triterpenoid
licochalcone e
licochalcone E: from roots of Glycyrrhiza inflata; structure in first source		2.6120
ConditionIndicatedRelationship StrengthStudiesTrials
Acute Liver Injury, Drug-Induced
[description not available]		02.1510
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.1510
Chemical and Drug Induced Liver Injury
A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, herbal and dietary supplements and chemicals from the environment.		02.1510
Carcinoma, Non-Small Cell Lung
[description not available]		02.2510
Cancer of Lung
[description not available]		02.2510
Carcinoma, Non-Small-Cell Lung
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.		02.2510
Lung Neoplasms
Tumors or cancer of the LUNG.		02.2510
Aging
The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.		02.3110
Malignant Melanoma
[description not available]		02.1710
Invasiveness, Neoplasm
[description not available]		02.1710
Melanoma
A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)		07.1710
Carcinoma, Squamous Cell of Head and Neck
[description not available]		02.2110
Cancer of Mouth
[description not available]		02.2110
Squamous Cell Carcinoma of Head and Neck
The most common type of head and neck carcinoma that originates from cells on the surface of the NASAL CAVITY; MOUTH; PARANASAL SINUSES, SALIVARY GLANDS, and LARYNX. Mutations in TNFRSF10B, PTEN, and ING1 genes are associated with this cancer.		02.2110
Mouth Neoplasms
Tumors or cancer of the MOUTH.		02.2110
Innate Inflammatory Response
[description not available]		02.1110
Injury, Myocardial Reperfusion
[description not available]		02.1110
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.1110